valsartan has been researched along with Atrial Fibrillation in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (34.78) | 29.6817 |
| 2010's | 17 (36.96) | 24.3611 |
| 2020's | 13 (28.26) | 2.80 |
| Authors | Studies |
|---|---|
| Ammendola, E; Boriani, G; Bottino, R; D'Andrea, A; Gasperetti, A; Golino, P; Lip, GYH; Masarone, D; Nigro, G; Pacileo, G; Proietti, R; Russo, V; Schiavone, M | 1 |
| Liu, H; Liu, X; Wang, L; Xu, Q; Zhang, L | 1 |
| Chen, H; Chen, M; Han, J; Jiang, J; Shu, Z; Sun, Z; Wang, Q; Wu, B; Xia, Q; Zhang, B; Zhao, J; Zheng, L; Zhou, D; Zhuo, C | 1 |
| Anand, I; Chiang, LM; Cikes, M; Claggett, B; Cunningham, J; Desai, AS; Gori, M; Lam, CSP; Linssen, G; McMurray, JJV; Milicic, D; Packer, M; Pfeffer, M; Planinc, I; Redfield, M; Senni, M; Shah, SJ; Solomon, SD; Sweitzer, N; Zile, MR | 1 |
| Benfari, G; Brunetti, ND; Cameli, M; Canepa, M; Carluccio, E; Ciccarelli, M; Cicoira, M; Citro, R; Corrado, E; Correale, M; De Carli, G; Degiovanni, A; Dini, FL; Emdin, M; Giannoni, A; Guaricci, AI; Loria, V; Malagoli, A; Mandoli, GE; Mazzeo, P; Mengoni, A; Moderato, L; Novo, G; Pasquini, A; Pastore, MC; Patti, G; Piscitelli, L; Pugliese, NR; Rosa, G; Santoro, C; Taddei, C | 1 |
| Abumayyaleh, M; Akin, I; Aweimer, A; Crack, C; Demmer, J; El-Battrawy, I; Mügge, A; Pilsinger, C; Zhou, X | 1 |
| Ahmad, J; Dominic, P; Mohammad, Z; Morin, D; Penagaluri, A; Sultan, A | 1 |
| Deng, CY; Deng, H; Fang, Y; Kuang, SJ; Li, LA; Li, Q; Li, QQ; Liu, Y; Peng, DW; Rao, F; Wei, W; Wu, SL; Xue, YM; Yang, H; Zeng, P; Zhang, MZ; Zhang, QH | 1 |
| Aili, A; Bate, B; Chen, P; Dan, S; Guo, J; Han, Z; Hou, D; Hu, G; Kuransi, A; Nay, X; Qiqike, B; Xia, B; Xie, J; Zhu, M | 1 |
| Deng, CY; Guo, HM; Li, X; Liu, FZ; Liu, Y; Rao, F; Wang, ZY; Wei, W; Wu, SL; Xue, YM; Yang, H; Zhang, MZ | 1 |
| Letizia, C; Petramala, L | 1 |
| Dong, Z; Li, G; Li, L; Liang, Y; Liu, E; Liu, T; Niu, X; Wang, J; Yang, Y; Zhao, Z | 1 |
| Li, CY; Li, SN; Xi, H; Zhang, JR; Zhao, L; Zhou, L | 1 |
| Li, CZ; Li, DS; Li, PH; Li, SX; Li, Y; Lu, YJ; Pan, ZW; Shi, L; Su, WZ; Sun, YL; Xue, GL; Zhang, Y; Zhao, Y; Zhou, Y | 1 |
| Dong, Z; Li, G; Li, L; Liang, Y; Liu, E; Liu, T; Niu, X; Qi, W; Zhao, Z | 1 |
| Caivano, M; Gubelli, S | 1 |
| Barlera, S; Cappellini, G; Cosmi, F; Disertori, M; Fabbri, G; Favero, C; Franzosi, MG; Latini, R; Maggioni, AP; Moroni, LA; Quintarelli, S; Staszewsky, L | 1 |
| Hang, P; Li, Y; Sun, D; Sun, L; Wang, X; Xu, W; Yun, F; Zhao, H; Zhao, J | 1 |
| Bethel, MA; Califf, RM; Chang, F; Disertori, M; Giles, TD; Haffner, SM; Holman, RR; Latini, R; Maggioni, AP; McMurray, JJ; Rutten, GE; Standl, E; Staszewsky, L; Sun, JL; Thomas, L; Tognoni, G | 1 |
| Alves, C; Carballo, S; Darbellay, P; Lebowitz, D; Moret, M; Sabeh, N | 1 |
| Ding, X; Geng, J; Gong, Y; Li, J; Li, W; Li, Y; Liu, L; Pan, Z; Tan, X; Wang, D; Wang, X; Yan, S; Yun, F; Zhao, H | 1 |
| Li, GP; Li, LF; Liang, YZ; Liu, T; Qi, WW; Xu, G; Ye, L | 1 |
| Corradi, L; Derosa, G; Ferrari, I; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Santoro, T; Zoppi, A | 1 |
| Huang, CX; Jiang, H; Li, GS; Okello, E; Tang, YH; Wang, X; Zhao, QY | 1 |
| Barlera, S; Di Pasquale, G; Disertori, M; Franzosi, MG; Latini, R; Lucci, D; Maggioni, AP; Staszewsky, L; Tognoni, G | 1 |
| Gillis, AM | 1 |
| Smit, MD; Van Gelder, IC | 1 |
| Tomoda, H | 1 |
| Barlera, S; Cosmi, F; Di Pasquale, G; Disertori, M; Franzosi, MG; Latini, R; Lombardi, F; Maggioni, AP; Zeni, P | 1 |
| Allhoff, T; Anand, IS; Cohn, JN; Drexler, H; Jantzen, F; Kempf, T; Kuskowski, M; Rector, TS; Tapken, H; Wollert, KC | 1 |
| Barlera, S; Carbonieri, E; Disertori, M; Favero, C; Franzosi, MG; Gulizia, M; Latini, R; Maggioni, AP; Masson, S; Pirelli, S; Pulitano, G; Staszewsky, L; Struck, J; Vago, T; Zdunek, D | 1 |
| Barlera, S; Bianconi, L; Disertori, M; Fabbri, G; Favero, C; Franzosi, MG; Latini, R; Lombardi, F; Lucci, D; Maggioni, AP; Quintarelli, S; Staszewsky, L | 1 |
| Bertocchi, F; Bicego, D; Correale, E; Disertori, M; Emanuelli, C; Fabbri, G; Franzosi, MG; Gramenzi, S; Latini, R; Maggioni, AP; Masson, S; Nicolis, EB; Proietti, G; Pulitanò, G; Raimondi, E; Staszewsky, L; Taddei, F; Tognoni, G; Wong, M | 1 |
| Acar, G; Akçay, A; Altun, B; Kaya, H; Köroğlu, S; Sökmen, A | 1 |
| Liew, R | 1 |
| Kanorskiĭ, SG; Shevelev, VI | 1 |
| Barlera, S; Carson, PE; Cerè, E; Cohn, JN; Glazer, R; Latini, R; Maggioni, AP; Masson, S; Singh, SN; Tognoni, G | 1 |
| Coleman, CI; Kalus, JS; White, CM | 1 |
| Califf, RM; Diaz, R; Ertl, G; Køber, L; Leimberger, JD; Maggioni, AP; Mareev, V; McMurray, JJ; Opolski, G; Pfeffer, MA; Rouleau, JL; Solomon, SD; Swedberg, K; Van de Werf, F; Velazquez, EJ; Zannad, F; Zelenkofske, S | 1 |
| Chrysant, GS; Chrysant, SG | 1 |
| Delise, P; Di Pasquale, G; Disertori, M; Franzosi, MG; Latini, R; Maggioni, AP; Staszewsky, L; Tognoni, G | 1 |
| Chu, S; Dong, D; Gong, YT; Han, W; Li, BX; Li, WM; Li, Y; Liu, W; Sheng, L; Xue, JY; Yang, BF; Zhang, L | 1 |
| Coleman, CI; Kluger, J; Makanji, S; White, CM | 1 |
| Burstein, B; Calderone, A; Nattel, S; Qi, XY; Yeh, YH | 1 |
| Hua, TA; Julius, S; Kjeldsen, SE; McInnes, GT; Schmieder, RE; Zanchetti, A | 1 |
| Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A | 1 |
5 review(s) available for valsartan and Atrial Fibrillation
| Article | Year |
|---|---|
Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aminobutyrates; Atrial Fibrillation; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Randomized Controlled Trials as Topic; Valsartan | 2022 |
Effect of sacubitril-valsartan on the incidence of atrial fibrillation: A meta-analysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Heart Failure; Humans; Incidence; Valsartan | 2023 |
[Almanac 2011: Cardiac arrhythmias and pacing. Review of selected studies that have driven recent advances in clinical cardiology -- by the Editors of the Network Task Force of the European Society of Cardiology].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Cardiac Resynchronization Therapy; Catheter Ablation; Clinical Trials as Topic; Death, Sudden, Cardiac; Defibrillators, Implantable; Evidence-Based Medicine; Humans; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Tetrazoles; Thromboembolism; Treatment Outcome; Valine; Valsartan; Ventricular Fibrillation | 2012 |
The impact of suppressing the renin-angiotensin system on atrial fibrillation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Combined Modality Therapy; Electric Countershock; Enalapril; Humans; Indoles; Losartan; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Secondary Prevention; Tetrazoles; Valine; Valsartan | 2006 |
The pleiotropic effects of angiotensin receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Diabetes Mellitus; Heart; Humans; Kidney; Losartan; Platelet Aggregation; Stroke; Tetrazoles; Uric Acid; Valine; Valsartan | 2006 |
18 trial(s) available for valsartan and Atrial Fibrillation
| Article | Year |
|---|---|
Sacubitril/Valsartan Can Reduce Atrial Fibrillation Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation.
Topics: Atrial Fibrillation; Catheter Ablation; Heart Failure; Humans; Recurrence; Treatment Outcome; Valsartan | 2023 |
Combined treatment with valsartan and fluvastatin to delay disease progression in nonpermanent atrial fibrillation with hypertension: A clinical trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Blood Pressure; Disease Progression; Drug Therapy, Combination; Female; Fluvastatin; Heart Rate; Humans; Hypertension; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Valsartan | 2020 |
Upstream therapeutic strategies of valsartan and fluvastatin on hypertensive patients with non-permanent atrial fibrillation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Blood Pressure; China; Disease Progression; Female; Fluvastatin; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Male; Middle Aged; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Valsartan | 2018 |
Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Double-Blind Method; Electrocardiography; Female; Fibrinolytic Agents; Guideline Adherence; Hemorrhage; Humans; Incidence; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Practice Guidelines as Topic; Practice Patterns, Physicians'; Proportional Hazards Models; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Telemetry; Tetrazoles; Thromboembolism; Time Factors; Treatment Outcome; Valine; Valsartan; Warfarin | 2013 |
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Topics: Aged; Atrial Fibrillation; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Risk Assessment; Risk Factors; Tetrazoles; Valine; Valsartan | 2013 |
Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Blood Pressure; China; Clinical Protocols; Electrocardiography, Ambulatory; Fatty Acids, Monounsaturated; Fluvastatin; Heart Failure; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Myocardial Infarction; Prospective Studies; Recurrence; Research Design; Risk Assessment; Risk Factors; Shock, Cardiogenic; Time Factors; Treatment Outcome; Valsartan | 2015 |
Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Double-Blind Method; Electrocardiography; Female; Humans; Male; Peptide Fragments; Procollagen; Ramipril; Recurrence; Tetrazoles; Valine; Valsartan | 2008 |
Valsartan for prevention of recurrent atrial fibrillation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Cardiomegaly; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Double-Blind Method; Female; Humans; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Recurrence; Tetrazoles; Valine; Valsartan | 2009 |
Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Diuretics; Electrophysiologic Techniques, Cardiac; Female; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Recurrence; Risk Factors; Tetrazoles; Valine; Valsartan | 2010 |
Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Biomarkers; Diabetic Angiopathies; Female; Growth Differentiation Factor 15; Heart Failure; Humans; Hypertension; Male; Middle Aged; Placebos; Prognosis; Regression Analysis; Risk Assessment; Risk Factors; Severity of Illness Index; Tetrazoles; Valine; Valsartan | 2010 |
Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Biomarkers; Epidemiologic Methods; Female; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptides; Prognosis; Secondary Prevention; Tetrazoles; Troponin T; Valine; Valsartan | 2011 |
Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Humans; Incidence; Italy; Male; Prognosis; Prospective Studies; Recurrence; Tetrazoles; Valine; Valsartan | 2011 |
Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF echocardiographic substudy.
Topics: Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Atrial Function, Left; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Echocardiography, Doppler; Female; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Recovery of Function; Risk Assessment; Secondary Prevention; Severity of Illness Index; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
[Comparative effects of nebivolol and valsartan on atrial electromechanical coupling in newly diagnosed stage 1 hypertensive patients].
Topics: Antihypertensive Agents; Atrial Fibrillation; Benzopyrans; Echocardiography, Doppler; Ethanolamines; Female; Humans; Hypertension; Male; Middle Aged; Nebivolol; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction.
Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Captopril; Cardiac Output, Low; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Double-Blind Method; Echocardiography; Humans; Italy; Prospective Studies; Recurrence; Research Design; Tetrazoles; Valine; Valsartan | 2006 |
Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Drug Therapy, Combination; Female; Humans; Hypertension; Incidence; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Amlodipine; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Electrocardiography; Female; Humans; Hypertension; Male; Middle Aged; Propafenone; Prospective Studies; Secondary Prevention; Tetrazoles; Valine; Valsartan | 2008 |
23 other study(ies) available for valsartan and Atrial Fibrillation
| Article | Year |
|---|---|
Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients.
Topics: Aminobutyrates; Atrial Fibrillation; Biphenyl Compounds; Cardiac Resynchronization Therapy; Heart Failure; Humans; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left | 2022 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Fibrillation; Biphenyl Compounds; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry.
Topics: Aged; Atrial Fibrillation; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2023 |
The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus.
Topics: Aged; Atrial Fibrillation; Diabetes Mellitus; Heart Failure; Humans; Stroke Volume; Tachycardia, Ventricular; Tetrazoles; Troponin I; Valsartan; Ventricular Function, Left | 2023 |
Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
Topics: Aminobutyrates; Angiotensins; Animals; Antihypertensive Agents; Atrial Fibrillation; Atrial Remodeling; Biphenyl Compounds; Drug Combinations; Hypertension; Neprilysin; Rats; Rats, Inbred SHR; Tetrazoles; Valsartan | 2023 |
Sacubitril/Valsartan Cannot Improve Cardiac Function Compared with Valsartan in Patients Suffering Nonvalvular Atrial Fibrillation without Systolic Heart Failure.
Topics: Atrial Fibrillation; Biomarkers; Heart Failure; Heart Failure, Systolic; Humans; Stroke Volume; Tetrazoles; Valsartan | 2023 |
High hydrostatic pressure induces atrial electrical remodeling through angiotensin upregulation mediating FAK/Src pathway activation.
Topics: Angiotensin I; Angiotensin II; Animals; Anti-Arrhythmia Agents; Atrial Appendage; Atrial Fibrillation; Atrial Remodeling; Cell Line, Tumor; Focal Adhesion Kinase 1; Humans; Hydrostatic Pressure; Mice; Myocytes, Cardiac; Peptide Fragments; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; src-Family Kinases; Up-Regulation; Valsartan | 2020 |
Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan).
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Anticoagulants; Atrial Fibrillation; Biphenyl Compounds; Cardiology; Drug Combinations; Humans; Neprilysin; Stroke; Tetrazoles; Valsartan | 2020 |
Sacubitril/Valsartan Decreases Atrial Fibrillation Susceptibility by Inhibiting Angiotensin II-Induced Atrial Fibrosis Through p-Smad2/3, p-JNK, and p-p38 Signaling Pathways.
Topics: Aminobutyrates; Angiotensin II; Animals; Atrial Fibrillation; Biphenyl Compounds; Fibrosis; Rats; Signal Transduction; Valsartan | 2022 |
Valsartan reduced the vulnerability to atrial fibrillation by preventing action potential prolongation and conduction slowing in castrated male mice.
Topics: Action Potentials; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Cells, Cultured; Connexin 43; Disease Models, Animal; Heart Conduction System; Heart Rate; Male; Mice, Inbred ICR; Myocytes, Cardiac; Orchiectomy; Potassium; Sodium; Testosterone; Time Factors; Valsartan | 2018 |
Case of a patient with heart failure, dilated cardiomyopathy and atrial fibrillation treated with sacubitril/valsartan.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Fibrillation; Biphenyl Compounds; Cardiomyopathy, Dilated; Drug Combinations; Heart Failure; Hospitalization; Humans; Male; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Valsartan inhibits transient receptor potential canonical-3 channel in canine atrial fibrillation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Disease Models, Animal; Dogs; Tetrazoles; TRPC Cation Channels; Valine; Valsartan | 2013 |
[Internal medicine in the hospital setting].
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Asymptomatic Diseases; Atrial Fibrillation; Biphenyl Compounds; Carotid Stenosis; Colchicine; Diuretics; Drug Combinations; Heart Failure; Hospitals; Humans; Internal Medicine; Liver Cirrhosis; Narcotics; Neprilysin; Pericarditis; Peritonitis; Pulmonary Disease, Chronic Obstructive; Respiratory Therapy; Spironolactone; Stroke; Tetrazoles; Valsartan | 2015 |
Valsartan Reduced Atrial Fibrillation Susceptibility by Inhibiting Atrial Parasympathetic Remodeling through MAPKs/Neurturin Pathway.
Topics: Animals; Atrial Fibrillation; Dogs; Female; Male; MAP Kinase Signaling System; Neurturin; Rats; Valsartan | 2015 |
Acetylcholine-regulated K+ current remodelling in the atrium after myocardial infarction and valsartan administration.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Appendage; Atrial Fibrillation; Heart Atria; Myocardial Infarction; Patch-Clamp Techniques; Potassium Channels; Rabbits; Tetrazoles; Valine; Valsartan | 2009 |
Angiotensin-receptor blockers for prevention of atrial fibrillation--a matter of timing or target?
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Humans; Tetrazoles; Valine; Valsartan | 2009 |
Valsartan and recurrent atrial fibrillation.
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Cardiomegaly; Drug Administration Schedule; Humans; Secondary Prevention; Tetrazoles; Valine; Valsartan | 2009 |
Valsartan and recurrent atrial fibrillation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Humans; Secondary Prevention; Tetrazoles; Valine; Valsartan | 2009 |
[Antihypertensive therapy and dynamics of vascular wall rigidity in elderly patients with non-valvular atrial fibrillation].
Topics: Aged; Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Arterial Pressure; Arteries; Atrial Fibrillation; Combined Modality Therapy; Drug Monitoring; Female; Fluorobenzenes; Humans; Hypertension; Male; Myocardial Infarction; Perindopril; Pulse Wave Analysis; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Tetrazoles; Treatment Outcome; Ultrasonography, Doppler, Duplex; Valine; Valsartan; Vascular Resistance | 2012 |
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Aged; Atrial Fibrillation; Comorbidity; Electrocardiography; Female; Heart Failure; Humans; Incidence; Male; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
The effects of cilazapril and valsartan on the mRNA and protein expressions of atrial calpains and atrial structural remodeling in atrial fibrillation dogs.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Fibrillation; Blotting, Western; Calpain; Cilazapril; Disease Models, Animal; Dogs; Female; Gene Expression; Gene Expression Regulation; Heart Atria; Male; Myocytes, Cardiac; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Ultrasonography; Valine; Valsartan | 2007 |
Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Biphenyl Compounds; Cardiac Surgical Procedures; Cohort Studies; Female; Humans; Irbesartan; Lisinopril; Male; Postoperative Complications; Ramipril; Retrospective Studies; Tetrazoles; Valine; Valsartan | 2007 |
Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: a novel consideration in atrial remodeling.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Cell Communication; Cell Proliferation; Cells, Cultured; Collagen Type I; Culture Media; Disease Models, Animal; Dogs; Extracellular Matrix; Fibroblasts; Fibronectins; Heterocyclic Compounds, 4 or More Rings; Muscle Contraction; Myocytes, Cardiac; Tachycardia; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2007 |